Nvidia’s $100 Billion OpenAI Investment Faces Internal Doubts, Report Says 
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz 
US Judge Rejects $2.36B Penalty Bid Against Google in Privacy Data Case 
Climate Adaptation at Home: How Irrigreen Makes Conservation Effortless 
Bob Iger Plans Early Exit as Disney Board Prepares CEO Succession Vote 
Sandisk Stock Soars After Blowout Earnings and AI-Driven Outlook 
CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
Panama Supreme Court Voids Hong Kong Firm’s Panama Canal Port Contracts Over Constitutional Violations 
OpenAI Reportedly Eyes Late-2026 IPO Amid Rising Competition and Massive Funding Needs 
Amazon Stock Dips as Reports Link Company to Potential $50B OpenAI Investment 
Pentagon and Anthropic Clash Over AI Safeguards in National Security Use 
American Airlines Plans Return to Venezuela Flights After U.S. Lifts Ban 
Apple Forecasts Strong Revenue Growth as iPhone Demand Surges in China and India 
Saks Global to End Saks on Amazon Partnership Amid Bankruptcy Restructuring 
SOUTH SAN FRANCISCO, Calif., May 25, 2017 -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, will present at the Jefferies 2017 Global Healthcare Conference. Sean McCarthy, D.Phil., president and chief executive officer will deliver a corporate overview on June 7, 2017, at 3:00 p.m. ET.
A live audio webcast of the presentation will be available through the Investors and News section of CytomX's website. An archived replay will be available for 90 days following the event.
About CytomX Therapeutics
CytomX is a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody technology platform. The Company uses its platform to create proprietary cancer immunotherapies against clinically-validated targets, such as PD-L1, and develop first-in-class cancer therapeutics against difficult-to-drug targets, such as CD166. Probody therapeutics are designed to take advantage of unique conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. The Company’s lead program, CX-072, a wholly-owned PD-L1-targeting Probody therapeutic, is being evaluated in a Phase 1/2 study. CX-072 is part of PROCLAIM (Probody Clinical Assessment In Man), an international umbrella clinical trial program that provides clinical trial sites with access to the Company’s novel therapies under one central protocol. The trial initiation for CX-2009, a first-in-class Probody drug conjugate targeting the highly expressed tumor antigen, CD166, is expected mid-2017. In addition to its proprietary programs, CytomX is collaborating with strategic partners, including AbbVie, Bristol-Myers Squibb Company, Pfizer Inc., MD Anderson Cancer Center and ImmunoGen, Inc. For more information, visit www.cytomx.com or follow us on Twitter.
Media Contact: Canale Communications Ian Stone [email protected] 619-849-5388 Investor Contact: Trout Group Pete Rahmer [email protected] 646-378-2973
